Delivery Order SPE2DB20D3101-SPE2DB25FRNF2
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on May 27, 2025, for the supply of Viberzi 100 mg tablets (60-count) with a contract value of $1,480.32. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of May 28, 2025. The contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This award represents a continuation of AmerisourceBergen's substantial role as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Viberzi 75 mg tablets (60 count) valued at $2,354.21. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of June 20, 2025. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Viberzi 100 mg tablets (60-count) valued at $1,914.82. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement valued through December 2026. The order is set to be completed by June 3, 2025, with...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,960.49 to AmerisourceBergen Drug Corp for the supply of Viberzi 100 mg tablets (60-count) on July 15, 2025, with completion scheduled for July 16, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is located in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 28, 2025, for the supply of Viberzi 75 mg tablets (60-count) with a ceiling value of $2,106.67. This firm fixed-price delivery order, which is expected to be completed by October 29, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The award was made without...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Viberzi 100 mg tablets (60-count) at a firm fixed price of $1,149.76, with an ultimate completion date of June 3, 2025. This is a non-set-aside competitive award issued as a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract number SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Viberzi 100 mg tablets (60-count units) under a firm fixed-price contract with a ceiling value of $1,716.59. The award, issued on June 9, 2025, with an ultimate completion date of June 10, 2025, represents a non-set-aside competitive procurement. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Viberzi 100 mg tablets (60-count) at a ceiling value of $3,587.92 under a firm fixed price contract. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The award was competitively determined with no...
- The Defense Logistics Agency awarded a delivery order valued at $1,707.63 to AmerisourceBergen Drug Corp for 60 tablets of Viberzi 100 mg on August 5, 2025, with an ultimate completion date of August 6, 2025. This is a firm fixed price, non-set-aside contract with performance occurring at the company's corporate office in Conshohocken, Pennsylvania. The award represents a competitive delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 12, 2025, for the supply of Viberzi 100 mg tablets (60-count units) with a ceiling value of $1,652.42. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The contract is set to be completed by November 13, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRNF2Delivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on June 18, 2025, for the supply of Viberzi 75 mg tablets (60-count units) with a ceiling value of $1,707.63. This competitively awarded, non-set-aside contract utilizes firm fixed-price pricing and is scheduled for completion by June 20, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as the comprehensive global pharmaceutical support vehicle for military healthcare programs. The DLA Troop Support Medical IDC enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical commodities to support federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard. Viberzi, a prescription medication used primarily for irritable bowel syndrome management, is distributed to military and veteran healthcare systems as part of the company's extensive portfolio of brand-name and generic pharmaceuticals. AmerisourceBergen's demonstrated capability in meeting federal procurement requirements through open competition and its significant standing as a critical pharmaceutical vendor within the federal medical supply chain position it to continue fulfilling specialized medication needs under the broader DLA pharmaceutical prime vendor framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 6/18/25 |